Use of the temporary glycemic target feature in the medtronic MiniMed™ 780G advanced hybrid closed loop system: a real-world evidence study
- 5 June 2025
- journal article
- research article
- Published by Springer Nature in Acta Diabetologica
- Vol. 62 (11) , 1953-1957
Abstract
Aim The MiniMed™ 780G system utilizes an Advanced Hybrid Closed-Loop algorithm, which is optimized to perform best at a glucose target of 100 mg/dL. The system also includes a temporary target feature (TT) of 150 mg/dL that can be set when higher glucose utilization is anticipated (e.g., exercise/strenuous work). Methods Real-world data from 1002 randomly selected users of the MiniMed™ 780G and MiniMed™ 670G systems were used to investigate the TT functionality (n = 501 MiniMed™ 780G users, n = 501 MiniMed™ 670G users). Continuous glucose monitoring (CGM) metrics were calculated for 4-h intervals (4 h prior to commencing TT use and 0–4, 4–8, 8–12, 12–16, 16–20 and 20–24 h after TT initiation). Results CGM results showed that, with both systems, the time-in-range (TIR) during TT periods mostly equalled or exceeded TIR in corresponding non-TT periods. In the first 4 h after TT initiation, the MiniMed™ 780G system demonstrated a TIR and time in tight range (TITR) of 71.6% and 46.4%, respectively, [a 1.6 (p = 0.11) and 2.6 (p = 0.009) percentage point benefit in TIR and TITR, respectively, versus the 670G system]. Mean time-below-range remained below target in both periods. Conclusions These findings confirm that the TT setting performs as intended, allowing users to maintain TIR during strenuous activity without compromising safety.Keywords
Funding Information
- Medtronic
This publication has 13 references indexed in Scilit:
- 6. Glycemic Goals and Hypoglycemia: Standards of Care in Diabetes—2025Diabetes Care, 2024
- A Peek Under the Hood: Explaining the MiniMed™ 780G Algorithm with Meal Detection TechnologyDiabetes Technology & Therapeutics, 2024
- Exercising Safely with the MiniMed™ 780G Automated Insulin Delivery SystemDiabetes Technology & Therapeutics, 2024
- Time in Tight Glucose Range in Type 1 Diabetes: Predictive Factors and Achievable Targets in Real-World Users of the MiniMed 780G SystemDiabetes Care, 2023
- Real‐world performance of the MiniMed 780G advanced hybrid closed loop system in Latin America: Substantial improvement in glycaemic control with each technology iteration of the MiniMed automated insulin delivery systemDiabetes, Obesity and Metabolism, 2023
- Impact of Temporary Glycemic Target Use in the Hybrid and Advanced Hybrid Closed-Loop SystemsDiabetes Technology & Therapeutics, 2022
- Predictors of time in target glucose range in real‐world users of the MiniMed 780G systemDiabetes, Obesity and Metabolism, 2022
- Exercise, Hypoglycemia, and Type 1 DiabetesDiabetes Technology & Therapeutics, 2014
- Preventing Exercise-Induced Hypoglycemia in Type 1 Diabetes Using Real-Time Continuous Glucose Monitoring and a New Carbohydrate Intake Algorithm: An Observational Field StudyDiabetes Technology & Therapeutics, 2011
- Continuous Glucose Monitoring Reveals Delayed Nocturnal Hypoglycemia After Intermittent High-Intensity Exercise in Nontrained Patients with Type 1 DiabetesDiabetes Technology & Therapeutics, 2010